Time-Dependent Effects on Coronary Remodeling and Epicardial Conductance After Intracoronary Injection of Enriched Hematopoietic Bone Marrow Stem Cells in Patients With Previous Myocardial Infarction
Abstract:Bone marrow (BM) cells may interact with coronary endothelium and modulate coronary atherosclerosis. We investigated the time course of coronary luminal loss and changes in conductance after intracoronary injection of enriched hematopoietic BM stem cells in patients with previous myocardial infarction (MI). Among 24 patients with acute MI, 13 were randomized to early (<7 days) and 11 to late (4 months) intracoronary injection of CD133+ cells after the infarction. Segmental quantitative coronary angiography and fractional flow reserve (FFR) measurements of the infarct-related (IR) artery (A) and contralateral artery (control) were performed. In the early group, at 4 months, cumulative luminal loss (LL) of the minimal luminal diameter (MLD) of the IRA distal to the stented segment was −0.39 (−0.51–0.10) mm (p < 0.05 vs. control). There was no further change in LL between 4 and 8 months [−0.09 (−0.26–0.15) mm]. In parallel, FFR decreased at 4 months [−0.16 (−0.26–0.001), p < 0.05 vs. control] but slightly increased from 4 to 8 months follow-up [+0.05 (−0.10–0.09)]. In the late group, LL of the MLD of the IRA distal to the stented segments was −0.12 (−0.47–0.07) mm (NS vs. control) at 4 months and further −0.07 (−0.25–0.05) mm (NS) between 4 and 8 months. At 8 months, the total LL of the MLD in the early and late group was only slightly higher compared to control [−0.34 (−0.48–−0.16), −0.36 (−0.69–−0.09), and −0.12 (−0.39–0.05) mm, respectively, NS]. Early intracoronary administration of hematopoietic BM stem cells in patients with previous MI is associated with accelerated luminal loss and reduced conductance of the infarct-related artery.
Document Type: Research Article
Affiliations: 1: Cardiovascular Center, OLV Ziekenhuis, Aalst, Belgium, Molecular Cardiology Unit, OLV Ziekenhuis, Aalst, Belgium 2: Cardiovascular Center, OLV Ziekenhuis, Aalst, Belgium 3: Molecular Cardiology Unit, OLV Ziekenhuis, Aalst, Belgium 4: Cell Therapy Unit, Flemish Red Cross, Gent, Belgium, University of Gent, Belgium 5: Cell Therapy Unit, Flemish Red Cross, Gent, Belgium 6: University of Gent, Belgium
Publication date: September 1, 2007
- Cell Transplantation publishes original, peer-reviewed research and review articles on the subject of cell transplantation and its application to human diseases. To ensure high-quality contributions from all areas of transplantation, separate section editors and editorial boards have been established. Articles deal with a wide range of topics including physiological, medical, preclinical, tissue engineering, and device-oriented aspects of transplantation of nervous system, endocrine, growth factor-secreting, bone marrow, epithelial, endothelial, and genetically engineered cells, among others. Basic clinical studies and immunological research papers are also featured. To provide complete coverage of this revolutionary field, Cell Transplantation will report on relevant technological advances, and ethical and regulatory considerations of cell transplants. Cell Transplantation is now an Open Access journal starting with volume 18 in 2009, and therefore there will be an inexpensive publication charge, which is dependent on the number of pages, in addition to the charge for color figures. This will allow work to be disseminated to a wider audience and also entitle the corresponding author to a free PDF, as well as prepublication of an unedited version of the manuscript.